Drug Profile
Research programme: cancer therapeutics - Vivesto
Alternative Names: Anticancer bio-regulators - VivestoLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Oasmia Pharmaceutical
- Developer Vivesto
- Class Antineoplastics; Cytostatics; Small molecules
- Mechanism of Action Alkylating agents; DNA cross linking agents; DNA intercalators; DNA synthesis inhibitors; Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Cancer in Sweden (IV)
- 08 Mar 2021 Preclinical development for Cancer is ongoing in Sweden
- 03 Mar 2021 Oasmia Pharmaceutical and Karolinska Institutet enter into a research collaboration for development of APIs for Cancer using the XR-17™ platform